Roquefort Therapeutics plc (LON:ROQ – Get Free Report) shares were down 1.1% during trading on Thursday . The company traded as low as GBX 4.50 ($0.06) and last traded at GBX 4.50 ($0.06). Approximately 332,329 shares traded hands during mid-day trading, an increase of 4% from the average daily volume of 319,000 shares. The stock had previously closed at GBX 4.55 ($0.06).
Roquefort Therapeutics Stock Performance
The firm has a market capitalization of £6.13 million, a P/E ratio of -381.25 and a beta of -0.03. The company has a 50-day moving average price of GBX 6.82 and a 200-day moving average price of GBX 6.95.
Roquefort Therapeutics Company Profile
Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.
Read More
- Five stocks we like better than Roquefort Therapeutics
- What Is WallStreetBets and What Stocks Are They Targeting?
- MarketBeat Week in Review – 4/15 – 4/19
- Are Penny Stocks a Good Fit for Your Portfolio?
- Comprehensive Analysis of PayPal Stock
- What Investors Need to Know to Beat the Market
- Intuitive Surgical Stock Can Trend Much Higher This Year
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.